Project NK-001-2 (Q3679046): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Changed label, description and/or aliases in de: translated_label) |
||
| label / de | label / de | ||
Projekt NK-001-2 | |||
Revision as of 14:45, 26 November 2021
Project Q3679046 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Project NK-001-2 |
Project Q3679046 in France |
Statements
421,650.09 Euro
0 references
648,692.45 Euro
0 references
65.0 percent
0 references
4 January 2016
0 references
20 November 2021
0 references
Centre Hospitalier Régional Universitaire de Montpellier
0 references
Le projet a pour but de développer un nouveau médicament pour le traitement du cancer basé sur l’efficacité des mécanismes naturels anti-leucémiques des cellules NK (Natural Killers). L'utilisation des cellules NK constitue aujourd'hui une alternative majeure pour le traitement de pathologies tumorales. Le projet explore également les applications des cellules NK avec les Mab (anticorps monoclonaux). (French)
0 references
The project aims to develop a new drug for the treatment of cancer based on the effectiveness of natural anti-leukemic mechanisms of NK cells (Natural Killers). The use of NK cells is now a major alternative for the treatment of tumour pathologies. The project also explores NK cell applications with Mab (monoclonal antibodies). (English)
18 November 2021
0 references
Identifiers
LR0002193
0 references